logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
J

Jingdong Zhang

liaoning cancer hospital & institute
H指数:30
被引数:5,072

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Anbenitamab in combination with chemotherapy in patients with HER2-positive gastric or gastroesophageal junction carcinoma who failed previous therapy containing trastuzumab: a multicenter, phase II study (KC-WISE 01)

阿本替尼（anbenitamab）联合化疗用于既往接受过含曲妥珠单抗（trastuzumab）治疗失败的HER2阳性胃或胃食管结合部癌患者的治疗：一项多中心、II期研究（KC-WISE 01）。

CANCER COMMUNICATIONS
IF24.9
2025-11-010
OAAI
Zhao, Chuanhua; Zhao, Jun; Chen, Yigui; Liu, Bo; Du, Yangfeng; Li, Chenglin; Zhang, Jingdong; Yang, Mudan; Liu, Ying; Bai, Yuxian; Li, Suyi; Zhang, Ruixing; Ning, Fangling; Liu, Yanping; Zou, Kai; Zhang, Qi; Xie, Yijiao; An, Yuping; Xu, Jianming
Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial

Finotonlimab (PD-1抑制剂) 联合贝伐单抗 (贝伐单抗生物仿制药) 作为晚期肝细胞癌的一线治疗: 一项随机2/3期试验

Signal Transduction and Targeted Therapy
IF52.7
2025-08-060
OAAI
Chuanhua Zhao; Yanqiao Zhang; Gang Wang; Jinfang Zheng; Weiqing Chen; Zheng Lu; Li Zhuang; Shanzhi Gu; Lei Han; Zhendong Zheng; Zujiang Yu; Yongsheng Yang; Hongmei Sun; Xiaoyong Wei; Ying Cheng; Hailan Lin; Bo Zhu; Guicheng Wu; Kaijian Lei; Wei Wang; Yuwen Wang; Kehe Chen; Ximing Xu; Cuiping Zheng; Yanzhi Bi; Sijuan Ding; Jingdong Zhang; Wei Li; Hailong Liu; Jun Wang; Xianling Liu; Yangfeng Du; Lianming Cai; Jingran Wang; Zhanxiong Luo; Baocai Xing; Jie Shen; Lin Yang; Jianbing Wu; Ou Jiang; Zhigang Peng; Xiuli Liu; Bangwei Cao; Liangfang Shen; Aibing Xu; Aimin Li; Shaojun Chen; Ting Fu; Jian Chen; Chuan Jin; Lei Zhang; Jun Lv; Chengwu Zhang; Xiaoman Zhang; Yu Wang; Huo Su; Qiang Zhou; Wenlin Gai; Liangzhi Xie; Jianming Xu
A randomized phase 2 study of HLX22 plus trastuzumab biosimilar HLX02 and XELOX as first-line therapy for HER2-positive advanced gastric cancer
MED
IF11.8
2024-10-011
PRE
Li, Ning; Qiu, Meng; Zhang, Yanqiao; Yang, Mudan; Lu, Linzhi; Li, Wei; Ma, Yuntao; Hou, Xiaoming; Sun, Guoping; Cai, Mingquan; Wang, Jingran; Lu, Jianwei; Zhong, Diansheng; Huo, Zhibin; Zhang, Jingdong; Yin, Xianli; Deng, Jun; Liu, Zimin; Pan, Hongming; Chen, Ye; Yang, Futang; Yu, Haoyu; Li, Jing; Wang, Qingyu; Zhu, Jun; Li, Jin
Irinotecan plus raltitrexed as second-line treatment in locally advanced or metastatic colorectal cancer patients: a prospective open-label, single-arm, multi-center, phase II study
BMC CANCER
IF3.4
2024-09-022
OAAI
Cheng, Yu; Teng, Zan; Zhang, Yanqiao; Jin, Bo; Zheng, Zhendong; Man, Li; Wang, Zhenghua; Teng, Yuee; Yu, Ping; Shi, Jing; Luo, Ying; Wang, Ying; Zhang, Jingdong; Zhang, Huijuan; Liu, Jiwei; Chen, Hao; Xiao, Jiawen; Zhao, Lei; Zhang, Lingyun; Jiang, Yu; Chen, Ying; Zhang, Jian; Wang, Chang; Liu, Sa; Qu, Jinglei; Qu, Xiujuan; Liu, Yunpeng

研究方向

暂未获取到该数据
Y
Yuxian Bai
H 指数:59论文数:366被引数:1.9万
X
Xiujuan Qu
H 指数:47论文数:399被引数:8,436
J
Jianming Xu
H 指数:56论文数:387被引数:2.7万
Y
Yanqiao Zhang
H 指数:40论文数:376被引数:8,367
Y
Yuanhe Wang
H 指数:15论文数:60被引数:883
X
Xianli Yin
H 指数:16论文数:78被引数:1,670
刘
刘云鹏
H 指数:43论文数:349被引数:8,592
H
Hongming Pan
H 指数:63论文数:371被引数:2.3万
徐
徐瑞华
H 指数:104论文数:1,475被引数:5.4万
L
Lin Shen
H 指数:62论文数:827被引数:2.7万